文献速递MDS 与骨髓增殖性肿瘤白血病

慢性粒单核细胞白血病中TET2突变数量、类型及功能定位的临床、分子与预后相关性:1084例患者研究

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
PubMed 文献 · Leukemia · 2019-12-13

这项多机构大样本研究(n=1084)分析了慢性粒单核细胞白血病(CMML)中TET2突变的数量、类型和位置及其与其他体细胞事件的相互作用。

要点

  • TET2突变见于56%的CMML患者,与生存优势相关(49 vs 30个月,p<0.0001)。
  • 多TET2突变(≥2个)和截短突变者生存更优(57个月和51个月,p<0.001)。
  • TET2突变可部分抵消ASXL1突变的不良预后,ASXL1WT/TET2MT基因型结局更好。

核心结论

  • TET2突变在CMML中与生存优势相关,多突变和截短突变者优势更明显。
  • TET2突变可部分减轻ASXL1突变的不良预后影响,改善风险分层。

研究设计与样本

  • 大型多机构回顾性研究,纳入1084例慢性粒单核细胞白血病(CMML)患者。
  • 分析TET2突变的数量、类型、功能定位及其他体细胞事件的相互作用。

主要发现

  • 与TET2野生型相比,TET2突变患者年龄更大、更多为发育异常型CMML、共突变数量更多且风险分层更低。
  • TET2突变与生存优势相关(49 vs 30个月,p<0.0001),多突变(≥2个)者57个月(p<0.001),截短突变者51个月(p<0.001)。
  • ASXL1突变的不良预后影响被并存的TET2突变部分抵消,ASXL1WT/TET2MT基因型结局更好。

关键数值与推荐

  • TET2突变患者中28%携带2个突变,1%携带3个,0.2%携带5个。
  • TET2突变者中位生存49个月,TET2野生型30个月(p<0.0001)。
  • 多TET2突变(≥2个)者中位生存57个月(p<0.001),截短TET2突变者51个月(p<0.001)。

临床怎么用

  • 在CMML风险分层中应考虑TET2突变数量、类型及与ASXL1突变的联合状态。
  • TET2突变尤其多突变或截短突变提示较好预后,可辅助临床决策。
  • ASXL1突变患者若并存TET2突变,其不良风险可能减轻,需综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Loss-of-function TET2 mutations (TET2MT) are frequent early clonal events in myeloid neoplasms and are thought to confer a fitness advantage to hematopoietic precursors. This large, multi-institutional study (n = 1084), investigated the TET2 mutational landscape and prognostic implications of the number, type, and location of TET2MT and the epistatic relationship with other somatic events in chronic myelomonocytic leukemia (CMML). Nine hundred and forty-two TET2MT were identified in 604 (56%) patients, of which 710 (75%) were predicted to be truncating (involving the catalytic domain). Three hundred and sixteen (29%) patients had ≥1 TET2MT, with 28%, 1%, and 0.2% harboring 2, 3, and 5 mutations, respectively. In comparison to TET2WT, TET2MT patients were older in age, more likely to have dysplastic CMML, a higher number of co-occurring mutations, and lower-risk stratification. Importantly, TET2MT were associated with a survival advantage (49 vs. 30 months, p < 0.0001), especially in the context of multiple TET2MT (≥2; 57 months, p < 0.001), and truncating TET2MT (51 months, p < 0.001). In addition, the adverse prognostic impact of ASXL1MT was partially mitigated by concurrent TET2MT, with the ASXL1WT/TET2MT genotype having better outcomes and resulting in further risk stratification of ASXL1 inclusive CMML prognostic models, in comparison to ASXL1MT alone.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Coltro G, Mangaonkar AA, Lasho TL, et al. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2019. PMID: 31836856. doi:10.1038/s41375-019-0690-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。